Tuesday, 7 November 2017

Cellular Tumor Antigen p53- Pipeline Review, analysis by stage of development and overview of key players involved (Aprea, CanBas, Critical Outcome Tech.)

A new research document with title ‘Cellular Tumor Antigen p53 {Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53} – Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as Aprea AB, CanBas Co Ltd, Critical Outcome Technologies Inc, Innovation Pharmaceuticals Inc, ORCA Therapeutics BV, OSE Immunotherapeutics, Quark Pharmaceuticals Inc. The report will help user gain market insights, future trends and growth prospects for forecast period of 2017 – 2022
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 26 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 5, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Colorectal Cancer, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatocellular Carcinoma, Melanoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Skin Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bacterial Infections, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Chemotherapy Effects, Esophageal Cancer, Glioma, Hematological Tumor, Hepatic – Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Liposarcoma, Malignant Mesothelioma, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Solid Tumor, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer) and Viral Infections.
The latest report Cellular Tumor Antigen p53 – Pipeline Review, H2 2017, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
– The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
– The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
– The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in the Report
Aprea AB
CanBas Co Ltd
Critical Outcome Technologies Inc
Innovation Pharmaceuticals Inc
ORCA Therapeutics BV
OSE Immunotherapeutics
Quark Pharmaceuticals Inc
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Overview
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Companies Involved in Therapeutics Development
Aprea AB
CanBas Co Ltd
Critical Outcome Technologies Inc
Innovation Pharmaceuticals Inc
ORCA Therapeutics BV
OSE Immunotherapeutics
Quark Pharmaceuticals Inc
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Drug Profiles
APR-246 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATRN-502 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene l
….Continued
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)